MX2022008099A - Tratamiento para el cancer con inhibidores de cdk12/13. - Google Patents
Tratamiento para el cancer con inhibidores de cdk12/13.Info
- Publication number
- MX2022008099A MX2022008099A MX2022008099A MX2022008099A MX2022008099A MX 2022008099 A MX2022008099 A MX 2022008099A MX 2022008099 A MX2022008099 A MX 2022008099A MX 2022008099 A MX2022008099 A MX 2022008099A MX 2022008099 A MX2022008099 A MX 2022008099A
- Authority
- MX
- Mexico
- Prior art keywords
- cancer
- cdk12
- inhibitors
- treatment
- compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6851—Quantitative amplification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Pathology (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Hospice & Palliative Care (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
En el presente documento se proporcionan composiciones y métodos para el tratamiento de cáncer de mama triple negativo, cáncer de ovario y cáncer de próstata resistente a la castración. Dichas composiciones comprenden inhibidores de CDK12/13.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962956114P | 2019-12-31 | 2019-12-31 | |
PCT/US2020/066967 WO2021138215A1 (en) | 2019-12-31 | 2020-12-23 | Treatment of cancer with cdk12/13 inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022008099A true MX2022008099A (es) | 2022-07-11 |
Family
ID=76686778
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022008099A MX2022008099A (es) | 2019-12-31 | 2020-12-23 | Tratamiento para el cancer con inhibidores de cdk12/13. |
Country Status (11)
Country | Link |
---|---|
US (1) | US20230074545A1 (es) |
EP (1) | EP4085053A4 (es) |
JP (1) | JP2023508996A (es) |
KR (1) | KR20220123064A (es) |
CN (1) | CN115175899A (es) |
AU (1) | AU2020417223A1 (es) |
BR (1) | BR112022012867A2 (es) |
CA (1) | CA3166386A1 (es) |
IL (1) | IL294392A (es) |
MX (1) | MX2022008099A (es) |
WO (1) | WO2021138215A1 (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3787629A4 (en) | 2018-05-02 | 2022-01-05 | Kinnate Biopharma Inc. | INHIBITORS OF CYCLINE-DEPENDENT KINASES |
AU2019291935A1 (en) | 2018-06-29 | 2021-02-04 | Kinnate Biopharma Inc. | Inhibitors of cyclin-dependent kinases |
US20230203010A1 (en) * | 2021-12-03 | 2023-06-29 | Incyte Corporation | Bicyclic amine cdk12 inhibitors |
US12084453B2 (en) | 2021-12-10 | 2024-09-10 | Incyte Corporation | Bicyclic amines as CDK12 inhibitors |
WO2024032561A1 (en) * | 2022-08-08 | 2024-02-15 | Insilico Medicine Ip Limited | Inhibitors of cyclin-dependent kinase (cdk) 12 and/or cdk13 and uses thereof |
WO2024175065A1 (zh) * | 2023-02-24 | 2024-08-29 | 中国科学院上海有机化学研究所 | 一类含有芳基取代的cdk12/13的降解剂,及其制备方法、药物组合物和应用 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG185952A1 (en) * | 2007-11-12 | 2012-12-28 | Bipar Sciences Inc | Treatment of breast cancer with 4-iodo-3-nitrobenzamide in combination with anti-tumor agents |
US20160264552A1 (en) * | 2013-10-18 | 2016-09-15 | Syros Pharmaceuticals, Inc. | Heteromaromatic compounds useful for the treatment of prolferative diseases |
EP3787629A4 (en) * | 2018-05-02 | 2022-01-05 | Kinnate Biopharma Inc. | INHIBITORS OF CYCLINE-DEPENDENT KINASES |
AU2019291935A1 (en) * | 2018-06-29 | 2021-02-04 | Kinnate Biopharma Inc. | Inhibitors of cyclin-dependent kinases |
-
2020
- 2020-12-23 EP EP20910551.9A patent/EP4085053A4/en active Pending
- 2020-12-23 WO PCT/US2020/066967 patent/WO2021138215A1/en unknown
- 2020-12-23 BR BR112022012867A patent/BR112022012867A2/pt not_active Application Discontinuation
- 2020-12-23 JP JP2022539279A patent/JP2023508996A/ja active Pending
- 2020-12-23 CN CN202080097606.5A patent/CN115175899A/zh active Pending
- 2020-12-23 IL IL294392A patent/IL294392A/en unknown
- 2020-12-23 AU AU2020417223A patent/AU2020417223A1/en active Pending
- 2020-12-23 MX MX2022008099A patent/MX2022008099A/es unknown
- 2020-12-23 US US17/789,484 patent/US20230074545A1/en active Pending
- 2020-12-23 CA CA3166386A patent/CA3166386A1/en active Pending
- 2020-12-23 KR KR1020227026204A patent/KR20220123064A/ko unknown
Also Published As
Publication number | Publication date |
---|---|
CA3166386A1 (en) | 2021-07-08 |
JP2023508996A (ja) | 2023-03-06 |
KR20220123064A (ko) | 2022-09-05 |
BR112022012867A2 (pt) | 2022-09-06 |
US20230074545A1 (en) | 2023-03-09 |
EP4085053A4 (en) | 2023-12-27 |
CN115175899A (zh) | 2022-10-11 |
EP4085053A1 (en) | 2022-11-09 |
WO2021138215A1 (en) | 2021-07-08 |
AU2020417223A1 (en) | 2022-07-14 |
IL294392A (en) | 2022-08-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022008099A (es) | Tratamiento para el cancer con inhibidores de cdk12/13. | |
MX2020012797A (es) | Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso. | |
PH12020551923A1 (en) | Methods and compositions for treating cancer | |
NZ754865A (en) | Combination therapy for the treatment of cancer | |
MX2019007030A (es) | Composiciones y metodos para el tratamiento del cancer. | |
MX2020012204A (es) | Inhibidores de kras g12c para tratar el cáncer. | |
MY196582A (en) | PD-1/PD-L1 Inhibitors | |
MX2021013218A (es) | Composiciones y metodos para el tratamiento del cancer usando una terapia con celulas t modificadas con tet2. | |
WO2018140831A3 (en) | Tumor targeting conjugates and methods of use thereof | |
MX2021005075A (es) | Metodos para el tratamiento de cancer de prostata resistente a la castracion y sensible a la castracion. | |
MX2023007841A (es) | Metodos, composiciones y componentes relacionados con crispr-cpf1 para la inmunoterapia contra el cancer. | |
EP4317422A3 (en) | Combinatorial cancer immunotherapy | |
MX2019003938A (es) | Compuestos espirociclicos. | |
PH12021551036A1 (en) | Anti-liv1 immune cell cancer therapy | |
MX2024000253A (es) | Inhibicion del smarca2 para el tratamiento del cancer. | |
MX2021008834A (es) | Metodos de tratamiento del cancer de mama con tucatinib. | |
TN2019000211A1 (en) | Antitumoral compounds | |
MY200161A (en) | Bacteria for targeting tumors and treating cancer | |
MX2018011875A (es) | Reprogramacion cardiaca directa mejorada. | |
MX2017012553A (es) | Compuestos espirociclicos. | |
MX2019015676A (es) | Uso de isovaleril espiramicina i, ii y/o iii en la fabricación de medicamentos para el tratamiento y/o la prevención de tumores, y el medicamento. | |
WO2020033019A3 (en) | Novel mct4 inhibitors and uses thereof | |
MX2020012990A (es) | Formulaciones de tegavivint y compuestos relacionados. | |
MX2023012515A (es) | Tratamiento del cancer con un inhibidor de raf. | |
WO2018193476A3 (en) | ANTICANCER COMPOUNDS |